BCR-ABL T315I
A gatekeeper change that makes most tyrosine kinase inhibitors no longer effective.
Parent marker: BCR-ABL
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
T315I limits the choice of inhibitors. The discussion shifts to drugs that are still active against these changes, with cardiovascular monitoring needing attention.
How this finding appears in a report
Checked via kinase domain sequencing after inadequate response.
When therapy stops working
Additional changes may appear after subsequent therapy so regular monitoring remains necessary.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: BCR-ABL
The presence of BCR-ABL opens up a category of specific tyrosine kinase inhibitors. Transcript levels are also used to monitor the depth of response to therapy.
A negative result does not always mean absent
Summary
- Gen
- BCR-ABL1
- Variant
- BCR-ABL1 T315I
- Alteration type
- Mutation
- Discussed in
- Leukemia
- Updated
- 2026-09-10
Other names in reports
T315I
Drugs discussed
Treatment categories
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- BCR-ABL
Biomarker
Reason: Related through a biomarker
- Leukemia
Cancer type
Reason: Related to this page
- Ponatinib
Drug
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.